YMYoshihito Morimoto

Yoshihito Morimoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshihito Morimoto has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Yoshiyuki Takahashi

    Nagoya University Graduate School of Medicine, Japan

    3 shared publications
  • Aya Miyazaki

    Department of Paediatric Cardiology, Department of Adult Congenital Heart Disease, Seirei Hamamatsu General Hospital , Hamamatsu

    2 shared publications
  • Hidenori Yamamoto

    Department of Paediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya Aichi, Japan

    2 shared publications
  • Hiroshi Nishikawa

    Department of Paediatric Cardiology, Chukyo Children Heart Centre, Japan. Community Health Care Organization Chukyo Hospital, Nagoya Aichi, Japan

    2 shared publications
  • Kiyotaka Go

    Nagoya Daigaku Daigakuin Igakukei Kenkyuka Igakubu, JAPAN

    2 shared publications
  • Naoki Ohashi

    Nagoya University Graduate School of Medicine, Japan

    2 shared publications

Latest Publications

  • Open Access

    Therapeutic Potential of Sodium–Glucose Cotransporter 2 Inhibitors for the Treatment of Refractory Haemorrhagic Protein-Losing Enteropathy in Patients with Congenital Heart Disease: A Case Series

    by Yoshihito Morimoto, Yasumi Nakashima, Yuri Murayama, Yoshiaki Kato, Kenichi Kurosaki, Nao Inoue, Aya Miyazaki, Hideo Ohuchi

    Background: Haemorrhagic protein-losing enteropathy (hPLE) with transfusion dependence is an extreme phenotype of PLE, which is caused by elevated central venous pressure (CVP) and is a debilitating, complex congenital heart disease (CHD) complication. We report cases in which sodium–glucose cotransporter 2 inhibitor (SGLT2i) use induced hPLE remission. Case Summary: Patient 1: The patient, a 22-year-old woman, had restrictive physiology after surgery for Shone’s complex with hPLE. Despite intensive diuretic treatment, she had massive ascites with a high CVP (16 mmHg) and required transfusions almost daily for 2 years. Patient 2: The patient, a 35-year-old woman, presented with hPLE after conversion of an atriopulmonary connection Fontan surgery to a total cavopulmonary connection. She also had a high CVP (25 mmHg), developed hPLE with transfusion dependence and had been receiving transfusions for 2 years. SGLT2i treatment was initiated for both patients, and they showed a marked diuretic response, leading to significant decongestion and weight loss. Gastrointestinal bleeding subsequently subsided. The patients’ haemoglobin levels stabilised without further transfusions, and serum albumin levels significantly improved, indicating hPLE reversal. Discussion: SGLT2is are highly effective in treating hPLE due to various congestive CHDs. The findings suggest that the SGLT2i therapeutic effects in hPLE may be mediated by potent reduction of CVP and interstitial congestion. Thus, SGLT2is may be an innovative treatment for refractory hPLE in patients with congestive CHD, regardless of whether they have undergone the Fontan procedure.

  • Open Access

    Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

    by Yoshihito Morimoto, Yoshiaki Sato, Katsuhiro Kato, Hidenori Yamamoto, Kentaro Suzuki, Kiyotaka Go, Yoshie Fukasawa, Naoki Ohashi, Yoshiyuki Takahashi, Taichi Kato

    Background: Although plexiform lesion (PL) formation in severe pulmonary arterial hypertension (PAH) is a therapeutic target, the mechanisms underlying their formation have not been fully elucidated. This study aimed to identify candidate proteins involved in PL formation by examining differentially expressed proteins (DEPs) in PAH lesions. Methods: Proteomic remodeling was assessed before and after the formation of PLs in a SU5416 combined with hypoxia (SuHx) rat model of severe PAH using laser-capture microdissection coupled with mass spectrometry. Unobstructed pulmonary arteries with medial hypertrophy (UMHPAs) and PLs from SuHx rats were subjected to qualitative and quantitative proteomics, revealing DEPs between these structures. Results: We identified 718 proteins with 58 DEPs, of which 31 were upregulated in UMHPAs and 27 were upregulated in PLs. Immunostaining confirmed that DEPs detected in our proteomic analysis were differentially expressed between UMHPAs and PLs. Among them, we focused on heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) as a candidate protein that may be strongly associated with PL formation because of its strong association with cell proliferation. siRNA knockdown of hnRNPA1 in hypoxia-treated pulmonary artery smooth muscle cells reduced pyruvate kinase M2 expression and significantly decreased proliferative capacity. Treatment of SuHx rats with hnRNPA1 inhibitors also suppressed pulmonary artery remodeling in PAH and PL formation. Conclusions: Several DEPs associated with PL formation but with unclear relevance to pulmonary artery remodeling in PAH were discovered. Among these, hnRNPA1, which was not detected in transcriptome analysis, may be important in PL formation.

  • Conception by assisted reproductive technology in infants with critical congenital heart disease in Japan

    by Yoshihito Morimoto, Kiyotaka Go, Hidenori Yamamoto, Yoshie Fukasawa, Michikazu Nakai, Eiji Morihana, Kazushi Yasuda, Hiroshi Nishikawa, Naoki Ohashi, Yoshiyuki Takahashi, et al.


  • Risk factors for absence of catch‐up growth in small for gestational age very low‐birthweight infants

    by Sakiko Arai, Yoshiaki Sato, Hideki Muramatsu, Hidenori Yamamoto, Fumiko Aoki, Yu Okai, Shinsuke Kataoka, Yu Hanada, Motoharu Hamada, Yoshihito Morimoto, et al.

    Background: Many small for gestational age (SGA) infants have catch‐up growth during the first 2 years of life, but approximately 10% have no catch‐up growth, and short stature continues into adulthood. Identification of risk factors for absence of catch‐up growth at an early age may be useful for earlier diagnosis and earlier treatment.Methods: This was a retrospective multicenter study. The subjects were SGA infants with very low‐birthweight (VLBW), who were followed up until the age of 3 years. The risk factors for absence of catch‐up growth were identified on statistical analysis.Results: Of the 217 SGA infants in this study, 181 were in the catch‐up group and 36 were in the no catch‐up group. The catch‐up rate was 83%. On multivariate analysis adjusted for gestational age, birthweight, birth height, and birth head circumference, multipara, Z and ΔZ scores of length at 12 months of corrected age, and the Z score of height at 24 months of corrected age were risk factors for lack of catch‐up at 3 years.Conclusions: The length Z and ΔZ scores at 12 months of corrected age may be useful for an earlier diagnosis and earlier initiation of growth hormone treatment in VLBW infants.


  • Atropine-induced monomorphic ventricular tachycardia in an adolescent: A rare case

    by Naoki Ohashi, Hiroshi Nishikawa, Shuichiro Yoshida, Atsuko Kato, Yoshihito Morimoto, Kimihiro Yoshii, Jun Sato


  • Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia

    by Yoshihito Morimoto, Nao Yoshida, Nozomu Kawashima, Kimikazu Matsumoto, Koji Kato

    Acute immune thrombocytopenia (ITP) is a common benign bleeding disorder of variable etiology characterized by isolated thrombocytopenia. Intravenous immunoglobulin (IVIG) treatment is generally given as an initial treatment to pediatric patients with ITP, but markers predictive of the response to IVIG remain poorly defined. We retrospectively evaluated whether clinical and laboratory findings before treatment could predict response to IVIG and progression to chronic ITP in Japanese children with ITP. Between April 1997 and December 2011, a total of 49 children with newly diagnosed ITP were initially treated with IVIG. Their medical records were retrospectively reviewed. In multivariate analyses, lower white blood cell (WBC) count was the only unfavorable factor for response to IVIG and progression to chronic ITP. Patients with WBC count 9/L had a lower probability of thrombocytopenia-free survival (41 vs. 77 %, P = 0.003) and a higher rate of progression to chronic ITP (29 vs. 6 %, P = 0.040) than those with WBC count ≥7.0 × 109/L. These results suggest that ITP with lower WBC count may represent a distinct subgroup requiring initial treatment other than IVIG.